These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37517865)

  • 61. Convergence or divergence: next frontiers toward globalization of current- and next-generation cell and gene therapies.
    Bachtarzi H
    Regen Med; 2022 May; 17(5):313-326. PubMed ID: 35287491
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in Japan.
    Nagai S; Sugiyama D
    Clin Ther; 2019 Jan; 41(1):174-184.e3. PubMed ID: 30528048
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.
    Plagnol AC; Rowley E; Martin P; Livesey F
    Regen Med; 2009 Jul; 4(4):549-59. PubMed ID: 19580404
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hurdles in gene therapy regulatory approval: a retrospective analysis of European Marketing Authorization Applications.
    Carvalho M; Martins AP; Sepodes B
    Drug Discov Today; 2019 Mar; 24(3):823-828. PubMed ID: 30579785
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Extent and content of data for regulatory submissions: First-in-human and marketing authorization--Viewpoint of US industry.
    Harris IR
    Biologicals; 2015 Sep; 43(5):402-5. PubMed ID: 26088904
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A critical assessment of the scientific basis, and implementation, of regulations for the safety assessment and marketing of innovative tobacco-related products.
    Combes RD; Balls M
    Altern Lab Anim; 2015 Sep; 43(4):251-90. PubMed ID: 26375889
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy Perspective.
    Dominici M; Nichols K; Srivastava A; Weiss DJ; Eldridge P; Cuende N; Deans RJ; Rasko JE; Levine AD; Turner L; Griffin DL; O'Donnell L; Forte M; Mason C; Wagena E; Janssen W; Nordon R; Wall D; Ho HN; Ruiz MA; Wilton S; Horwitz EM; Gunter KC;
    Cytotherapy; 2015 Dec; 17(12):1663-6. PubMed ID: 26589750
    [No Abstract]   [Full Text] [Related]  

  • 68. Unproven stem cell interventions: A global public health problem requiring global deliberation.
    Master Z; Matthews KRW; Abou-El-Enein M
    Stem Cell Reports; 2021 Jun; 16(6):1435-1445. PubMed ID: 34107243
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.
    Ogbogu U; Du J; Koukio Y
    BMC Med Ethics; 2018 May; 19(1):32. PubMed ID: 29716594
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The early career researcher's toolkit: translating tissue engineering, regenerative medicine and cell therapy products.
    Rafiq QA; Ortega I; Jenkins SI; Wilson SL; Patel AK; Barnes AL; Adams CF; Delcassian D; Smith D
    Regen Med; 2015 Nov; 10(8):989-1003. PubMed ID: 26628407
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Proceedings: international regulatory considerations on development pathways for cell therapies.
    Feigal EG; Tsokas K; Viswanathan S; Zhang J; Priest C; Pearce J; Mount N
    Stem Cells Transl Med; 2014 Aug; 3(8):879-87. PubMed ID: 25038248
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The European hospital exemption clause-new option for gene therapy?
    Buchholz CJ; Sanzenbacher R; Schüle S
    Hum Gene Ther; 2012 Jan; 23(1):7-12. PubMed ID: 22247961
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
    Lucas-Samuel S; Ferry N; Trouvin JH
    Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Uncovering the gray zone: mapping the global landscape of direct-to-consumer businesses offering interventions based on secretomes, extracellular vesicles, and exosomes.
    Asadpour A; Yahaya BH; Bicknell K; Cottrell GS; Widera D
    Stem Cell Res Ther; 2023 May; 14(1):111. PubMed ID: 37138298
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A few ethical issues in translational research for gene and cell therapy.
    Riva L; Petrini C
    J Transl Med; 2019 Nov; 17(1):395. PubMed ID: 31779636
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Regulatory Pathway for Advanced Cell Therapy and Gene Therapy Products in Brazil: A Road to Be Built.
    de Freitas DR
    Adv Exp Med Biol; 2015; 871():213-9. PubMed ID: 26374221
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [The Innovation Office of the Paul-Ehrlich-Institut. Regulatory support during the scientific development of ATMP].
    Ziegele B; Dahl L; Müller AT
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):857-66. PubMed ID: 21698540
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Regulation of Clinical Research for Cellular and Gene Therapy Products in India.
    Dalal V; Lata H; Kharkwal G; Jotwani G
    Adv Exp Med Biol; 2023; 1430():135-154. PubMed ID: 37526846
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mapping and driving the stem cell ecosystem.
    Knoepfler PS
    Regen Med; 2018 Oct; 13(7):845-858. PubMed ID: 30289055
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Regulatory requirements for clinical trial and marketing authorisation application for cell-based medicinal products.
    Salmikangas P; Flory E; Reinhardt J; Hinz T; Maciulaitis R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):24-9. PubMed ID: 19940964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.